ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 102 filers reported holding ORIC PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,964,330 | -12.3% | 820,447 | +12.5% | 0.00% | 0.0% |
| Q2 2023 | $5,660,004 | +223.0% | 729,382 | +137.3% | 0.00% | – |
| Q1 2023 | $1,752,305 | +104765.6% | 307,422 | +8.4% | 0.00% | – |
| Q4 2022 | $1,671 | -99.8% | 283,711 | -0.2% | 0.00% | – |
| Q3 2022 | $909,000 | -37.4% | 284,308 | -12.4% | 0.00% | – |
| Q2 2022 | $1,453,000 | -53.0% | 324,373 | -44.0% | 0.00% | – |
| Q1 2022 | $3,090,000 | -65.9% | 578,822 | -6.0% | 0.00% | -100.0% |
| Q4 2021 | $9,053,000 | -33.5% | 615,872 | -5.4% | 0.00% | -50.0% |
| Q3 2021 | $13,617,000 | +88.7% | 651,224 | +59.7% | 0.00% | +100.0% |
| Q2 2021 | $7,215,000 | -12.5% | 407,881 | +21.2% | 0.00% | 0.0% |
| Q1 2021 | $8,243,000 | -22.6% | 336,463 | +7.0% | 0.00% | -50.0% |
| Q4 2020 | $10,645,000 | +204.9% | 314,500 | +125.3% | 0.00% | +100.0% |
| Q3 2020 | $3,491,000 | -25.1% | 139,605 | +1.1% | 0.00% | 0.0% |
| Q2 2020 | $4,658,000 | – | 138,126 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 4,768,181 | $161,403,000 | 14.64% |
| Invus Financial Advisors, LLC | 1,007,575 | $34,106,000 | 14.26% |
| Euclidean Capital LLC | 1,400,435 | $47,405,000 | 10.04% |
| Memorial Sloan Kettering Cancer Center | 602,272 | $20,387,000 | 8.63% |
| EcoR1 Capital, LLC | 3,092,218 | $104,672,000 | 5.63% |
| Ally Bridge Group (NY) LLC | 413,061 | $13,982,000 | 2.40% |
| Asymmetry Capital Management, L.P. | 67,210 | $2,275,000 | 1.04% |
| Orbimed Advisors | 2,921,967 | $98,909,000 | 0.86% |
| Casdin Capital, LLC | 601,515 | $20,361,000 | 0.60% |
| EMERALD ADVISERS, LLC | 522,302 | $17,680,000 | 0.59% |